Calendar

Week of Jan 17, 2022

Jan 21, 2022approval1663d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

Jan 21, 2022approval1663d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

Jan 21, 2022approval1663d agoTECENTRIQ (ATEZOLIZUMAB) — FDA approvalatezolizumab

Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

Jan 21, 2022approval1663d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

Jan 26, 2022approval1658d agoPOMALIDOMIDE — FDA approvalPOMALIDOMIDE

Sponsor: MYLAN. Form: CAPSULE. Route: ORAL

Jan 27, 2022approval

Jan 31, 2022approval1653d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalPrinston Pharmaceutical Inc

Sponsor: TEVA. Form: TABLET. Route: ORAL

Jan 31, 2022approval

Feb 7, 2022approval1646d agoCABENUVA KIT (CABOTEGRAVIR) — FDA approvalViiV Healthcare Company

Sponsor: VIIV HLTHCARE. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

Feb 8, 2022approval

Feb 14, 2022approval1639d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

Feb 15, 2022approval

Feb 22, 2022approval1631d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

Feb 23, 2022approval

← prev

page 1 of 125